Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2014 1
2016 4
2017 4
2018 6
2019 4
2020 5
2021 9
2022 10
2023 10
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Results by year

Filters applied: . Clear all
Page 1
Downregulation of the FTO m6A RNA demethylase promotes EMT-mediated progression of epithelial tumors and sensitivity to Wnt inhibitors.
Jeschke J, Collignon E, Al Wardi C, Krayem M, Bizet M, Jia Y, Garaud S, Wimana Z, Calonne E, Hassabi B, Morandini R, Deplus R, Putmans P, Dube G, Singh NK, Koch A, Shostak K, Rizzotto L, Ross RL, Desmedt C, Bareche Y, Rothé F, Lehmann-Che J, Duterque-Coquillaud M, Leroy X, Menschaert G, Teixeira L, Guo M, Limbach PA, Close P, Chariot A, Leucci E, Ghanem G, Yuan BF, Willard-Gallo K, Sotiriou C, Marine JC, Fuks F. Jeschke J, et al. Among authors: krayem m. Nat Cancer. 2021 Jun;2(6):611-628. doi: 10.1038/s43018-021-00223-7. Epub 2021 Jun 23. Nat Cancer. 2021. PMID: 35121941 Free PMC article.
Erratum: Krayem, M., et al. Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance Short Title: Sensitivity Prediction to MAPK Inhibitors in Melanoma. Cancers 2020, 12, 512.
Krayem M, Aftimos P, Najem A, Hooven TVD, Berg AVD, Hovestad-Bijl L, Wijn R, Hilhorst R, Ruijtenbeek R, Sabbah M, Kerger J, Awada A, Journe F, Ghanem GE. Krayem M, et al. Cancers (Basel). 2020 Oct 14;12(10):2981. doi: 10.3390/cancers12102981. Cancers (Basel). 2020. PMID: 33066704 Free PMC article.
New horizons in early drugs development in solid cancers.
Kotecki N, Kindt N, Krayem M, Awada A. Kotecki N, et al. Among authors: krayem m. Curr Opin Oncol. 2021 Sep 1;33(5):513-519. doi: 10.1097/CCO.0000000000000766. Curr Opin Oncol. 2021. PMID: 34310410 Review.
RTK Inhibitors in Melanoma: From Bench to Bedside.
Sabbah M, Najem A, Krayem M, Awada A, Journe F, Ghanem GE. Sabbah M, et al. Among authors: krayem m. Cancers (Basel). 2021 Apr 2;13(7):1685. doi: 10.3390/cancers13071685. Cancers (Basel). 2021. PMID: 33918490 Free PMC article. Review.
56 results